BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 24935480)

  • 21. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delayed fingolimod-associated asystole.
    Espinosa PS; Berger JR
    Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fingolimod for multiple sclerosis: a review for the specialist nurse.
    Harrison K
    Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
    Komoly S
    Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A; Montalban X
    Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fingolimod-associated amenorrhea: a report of three cases.
    Alroughani R
    Mult Scler; 2014 Oct; 20(12):1662-4. PubMed ID: 24515730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
    Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
    Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod.
    Prescrire Int; 2011; 20(118):173-4, 176-7. PubMed ID: 21751747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb; 8(2):98. PubMed ID: 19180099
    [No Abstract]   [Full Text] [Related]  

  • 34. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K; Adachi K
    Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 36. Gilenya safety update: cardiac and macula.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2012 Nov; 23(6):457-9. PubMed ID: 23047163
    [No Abstract]   [Full Text] [Related]  

  • 37. Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions.
    Mehling M; Kappos L; Derfuss T
    Curr Neurol Neurosci Rep; 2011 Oct; 11(5):492-7. PubMed ID: 21789537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract]   [Full Text] [Related]  

  • 39. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
    Tully T; Barkley A; Silber E
    Neurology; 2015 May; 84(19):1999-2001. PubMed ID: 25878178
    [No Abstract]   [Full Text] [Related]  

  • 40. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O; Küry P; Kieseier B; Hartung HP
    Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.